ReviewTranslational cancer research2026
Targeting the MICA/B-NKG2D axis in cancer: from molecular structure to immunotherapeutic strategies-a narrative review.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The interaction between major histocompatibility complex class I chain-related proteins A and B (MICA/B) and the activating receptor natural killer group 2 member D (NKG2D) represents a critical axis in anti-tumor immunity. This pathway plays a central role in the recognition and elimination of stressed or transformed cells by natural killer (NK) cells and CD8 Methods: A systematic literature search is conducted using PubMed databases to identify recent studies related to the structure, regulation, and therapeutic targeting of the MICA/B-NKG2D axis. Relevant experimental and clinical studies are analyzed, and a narrative review is performed to synthesize current knowledge and emerging insights. Key Content and Findings: This review first summarizes the molecular structure of MICA/B and the structural basis of their interaction with NKG2D, highlighting the functional impact of polymorphisms. It then outlines the multi-layered regulatory mechanisms governing MICA/B expression, including transcriptional, epigenetic, and post-translational regulation, with particular emphasis on proteolytic shedding mediated by a disintegrin and metalloproteinases (ADAMs) and matrix metalloproteinases (MMPs). The immunosuppressive role of soluble MICA/B in downregulating NKG2D expression and inducing effector cell dysfunction is discussed in detail. Furthermore, the role of the tumor microenvironment (TME) in modulating this axis through stromal cells, immune cells, metabolic stress, and extracellular vesicles is comprehensively analyzed. Finally, emerging therapeutic strategies targeting this pathway-including shedding inhibitors, expression enhancers, cellular therapies, and combination approaches-are critically evaluated. Conclusions: The MICA/B-NKG2D axis is a key regulator of tumor immune surveillance and a major target of tumor immune evasion. Its dysregulation is driven by complex and multilayered mechanisms involving tumor-intrinsic alterations and the TME. Therapeutic strategies aimed at restoring this axis show promising clinical potential, although challenges such as ligand polymorphism, soluble ligand interference, and on-target toxicity remain. A deeper understanding of the regulatory network and rational design of combination therapies will be essential for translating this pathway into effective cancer immunotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.